JP2017514850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514850A5 JP2017514850A5 JP2016566238A JP2016566238A JP2017514850A5 JP 2017514850 A5 JP2017514850 A5 JP 2017514850A5 JP 2016566238 A JP2016566238 A JP 2016566238A JP 2016566238 A JP2016566238 A JP 2016566238A JP 2017514850 A5 JP2017514850 A5 JP 2017514850A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- htbz
- isoquinolin
- hours
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989240P | 2014-05-06 | 2014-05-06 | |
| US61/989,240 | 2014-05-06 | ||
| PCT/US2015/029519 WO2015171802A1 (en) | 2014-05-06 | 2015-05-06 | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019181949A Division JP2019218407A (ja) | 2014-05-06 | 2019-10-02 | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514850A JP2017514850A (ja) | 2017-06-08 |
| JP2017514850A5 true JP2017514850A5 (cg-RX-API-DMAC7.html) | 2018-06-14 |
| JP6635945B2 JP6635945B2 (ja) | 2020-01-29 |
Family
ID=53264772
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566238A Active JP6635945B2 (ja) | 2014-05-06 | 2015-05-06 | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
| JP2019181949A Withdrawn JP2019218407A (ja) | 2014-05-06 | 2019-10-02 | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
| JP2021153918A Withdrawn JP2021191799A (ja) | 2014-05-06 | 2021-09-22 | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
| JP2024122223A Pending JP2024153782A (ja) | 2014-05-06 | 2024-07-29 | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019181949A Withdrawn JP2019218407A (ja) | 2014-05-06 | 2019-10-02 | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
| JP2021153918A Withdrawn JP2021191799A (ja) | 2014-05-06 | 2021-09-22 | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
| JP2024122223A Pending JP2024153782A (ja) | 2014-05-06 | 2024-07-29 | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
Country Status (24)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240304T1 (hr) * | 2015-10-30 | 2024-05-10 | Neurocrine Biosciences, Inc. | Soli valbenazin dihidroklorida i njihovi polimorfi |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| ES2811048T3 (es) * | 2016-06-29 | 2021-03-10 | Crystal Pharmaceutical Suzhou Co Ltd | Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas |
| EP4400171A3 (en) * | 2016-12-02 | 2024-09-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| KR20190108146A (ko) | 2017-01-27 | 2019-09-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CA3054238A1 (en) | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JP7250692B2 (ja) * | 2017-04-01 | 2023-04-03 | アデプティオ ファーマシューティカルズ リミテッド | 運動障害の治療における使用のためのジヒドロテトラベナジン |
| US20180280374A1 (en) * | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US20190111035A1 (en) * | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US20200179352A1 (en) * | 2017-04-26 | 2020-06-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| CA3081709A1 (en) * | 2017-11-08 | 2019-05-16 | Yuhua Li | Esters of dihydrotetrabenazine |
| EP3733666B1 (en) | 2017-12-26 | 2022-09-21 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof |
| EP3784237B1 (en) * | 2018-04-25 | 2023-11-01 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| WO2019241555A1 (en) | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| JOP20200336A1 (ar) | 2018-08-15 | 2020-12-22 | Neurocrine Biosciences Inc | طرق إعطاء مثبطات vmat2 معينة |
| WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| WO2020227672A1 (en) * | 2019-05-09 | 2020-11-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039627B2 (en) * | 2006-11-08 | 2011-10-18 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
| WO2008060451A2 (en) * | 2006-11-09 | 2008-05-22 | New York University | Graded glass/zirconia/glass structures for damage resistant ceramic dental and orthopedic prostheses |
| WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| HUE038158T2 (hu) | 2008-09-18 | 2018-09-28 | Auspex Pharmaceuticals Inc | Deuterizált benzokinolizin származékok vezikuláris monoamin transzporter-2 inhibitorként |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| CA2883641C (en) * | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CN113413385A (zh) * | 2014-02-07 | 2021-09-21 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
-
2015
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/da active
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/it unknown
- 2015-05-06 ES ES21178882T patent/ES2976207T3/es active Active
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/ko not_active Ceased
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/ko not_active Ceased
- 2015-05-06 MX MX2016014429A patent/MX387625B/es unknown
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/ko active Pending
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 SI SI201532006T patent/SI3936130T1/sl unknown
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 RS RS20240380A patent/RS65359B1/sr unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/es active Active
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/da active
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/lt unknown
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/ru active
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en not_active Withdrawn
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/hu unknown
- 2015-05-06 PL PL15724438T patent/PL3139925T3/pl unknown
- 2015-05-06 RS RS20220008A patent/RS62782B1/sr unknown
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/lt unknown
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/hr unknown
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/zh active Pending
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/zh active Pending
- 2015-05-06 SI SI201531799T patent/SI3139925T1/sl unknown
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/it unknown
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/hr unknown
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/ko not_active Ceased
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/ja active Active
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/hu unknown
- 2015-05-06 PT PT157244385T patent/PT3139925T/pt unknown
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/fi active
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/pl unknown
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/zh active Pending
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/ko not_active Ceased
- 2015-05-06 PT PT211788823T patent/PT3936130T/pt unknown
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en not_active Ceased
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
-
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/ja not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
-
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/ja not_active Withdrawn
-
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/el unknown
-
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514850A5 (cg-RX-API-DMAC7.html) | ||
| JP6635945B2 (ja) | 多動性運動障害を処置するためのｖｍａｔ２インヒビター | |
| PH12020550238A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| JP7221922B2 (ja) | 組み合せ抗細菌組成物および短期抗細菌レジメン | |
| JP2017525718A5 (cg-RX-API-DMAC7.html) | ||
| RU2013113222A (ru) | Способы лечения или профилактики тромбообразования или эмболии | |
| BR112014003061A2 (pt) | composição farmacêutica com sabor mascarado | |
| JP2016540738A5 (cg-RX-API-DMAC7.html) | ||
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| WO2011113802A3 (en) | Imidazopyridine and purine compounds, compositions and methods of use | |
| RU2014102362A (ru) | Антитромботические соединения | |
| WO2013022783A3 (en) | Progesterone containing oral dosage forms and related methods | |
| WO2016210003A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| JP2013508289A5 (cg-RX-API-DMAC7.html) | ||
| JP2012502047A5 (cg-RX-API-DMAC7.html) | ||
| JP2017513809A5 (cg-RX-API-DMAC7.html) | ||
| JP2015509539A5 (cg-RX-API-DMAC7.html) | ||
| PH12022550790A1 (en) | Oral complement factor d inhibitors | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| PH12022550794A1 (en) | Oral complement factor d inhibitors | |
| JP2015504094A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512247A5 (cg-RX-API-DMAC7.html) | ||
| RU2019109695A (ru) | Лекарственная форма для пролонгированного ослабления симптомов | |
| JP2016515550A5 (cg-RX-API-DMAC7.html) |